Baxter Richard B 4/A

What Happened
Richard B. Baxter, a director of Pelthos Therapeutics, was granted 19,108 restricted stock units (RSUs) on 2025-07-02. The award is reported as an acquisition (code A) at $0.00 per share (total reported value $0) because these RSUs are compensation rather than a cash purchase.

Key Details

• Transaction date: 2025-07-02 (reported on amended Form 4 filed 2026-04-01).
• Transaction type/code: Grant/Award (A) of 19,108 RSUs at $0.00.
• Shares owned after transaction: Not specified in this amended filing.
• Vesting: RSUs vest in equal quarterly installments over three years, subject to continued service as a director.
• Settlement: Each RSU represents the right to receive one share of common stock and may be settled solely in shares.
• Purpose: RSUs were granted as board compensation under the Issuer’s 2023 Equity Incentive Plan.
• Filing notes: This is an amendment that moves the originally reported grant from Table II to Table I. The amendment was filed ~9 months after the grant date. Exhibit 24 (Power of Attorney) is attached.

Context
RSU grants are a common form of compensation and are primarily a retention mechanism because shares vest over time; they do not reflect an immediate purchase or sale by the insider. Because this is an amended and belated filing, investors may view it as a reporting correction rather than a new trading signal; Form 4s are normally due within two business days of the transaction.